By Ronald A Li, PhD, CEO and Co-Founder, Medera, and Kevin D Costa, PhD, Co-Founder, Novoheart. Recent NIH policy prioritising the use of New Approach Methodologies (NAMs) as alternatives to laboratory animals in all new funding opportunities marks a seismic shift in how biomedical research will be conducted. For a company like Medera—built entirely around […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!